Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 6/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14427178 | 0.94 | MAOB (0.52) | TAAR1MEN1KMT2APTGES2CA12 | |
| SCHEMBL5545168 | 0.87 | TAAR1 (0.45) | TAAR1MEN1KMT2APTGES2CA12 | |
| SCHEMBL198598 | 0.84 | TAAR1 (0.50) | TAAR1MEN1KMT2APTGES2CA12 | |
| SCHEMBL27804764 | 0.82 | TAAR1 (0.48) | TAAR1MEN1KMT2APTGES2CA12 | |
| SCHEMBL2377606 | 0.80 | TAAR1 (0.46) | TAAR1KMT2APTGES2CA12CA1 | |
| SCHEMBL66512 | 0.80 | APLNR (0.50) | TAAR1PTGES2CA12CA1CA2 | |
| SCHEMBL29001383 | 0.80 | MGLL (0.47) | TAAR1MEN1KMT2APTGES2CA12 | |
| SCHEMBL8113789 | 0.80 | RECQL (0.64) | TAAR1MEN1KMT2APTGES2CA12 | |
| SCHEMBL3135932 | 0.80 | TAAR1 (0.46) | TAAR1MEN1KMT2APTGES2CA12 | |
| SCHEMBL6646604 | 0.80 | TAAR1 (0.46) | TAAR1MEN1KMT2APTGES2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-02-27 | — | — | US | disclosed |
| EP-3541804-B1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3541810-B1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3541792-B1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-108137545-B | Triazole agonists of the APJ receptor | 美国安进公司 | 2020-09-22 | — | — | CN | disclosed |
| WO-2004052851-A1 | PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
| EP-0882023-B1 | HISTAMINE H 3 RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-6080871-A | ANTIHISTAMINES | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-06-27 | — | — | US | disclosed |
| CN-1215392-A | Histamine H3 receptor ligands | BLACK JAMES FOUNDATION (GB) | 1999-04-28 | — | — | CN | disclosed |
| EP-0882023-A1 | HISTAMINE H 3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997029092-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-08-14 | — | — | WO | disclosed |
| US-4443477-A | ANTICOAGULANTS, ANTILIPEMIC AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1984-04-17 | — | — | US | disclosed |
| EP-0004011-B1 | PHENOXYALKYLCARBOXYLIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1981-04-01 | — | — | EP | disclosed |
| US-4258058-A | Phenoxyalkylcarboxylic acid compounds and thrombocyte-aggregation inhibition | BOEHRINGER MANNHEIM GMBH (DE) | 1981-03-24 | — | — | US | disclosed |
| EP-0004011-A1 | Phenoxyalkylcarboxylic-acid derivatives, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1979-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | TAAR1 207/4885MEN1 4391/4885KMT2A 3480/4885 |
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | TAAR1 139/4885MEN1 4578/4885KMT2A 4489/4885 |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | TAAR1 257/4885MEN1 4636/4885KMT2A 3930/4885 |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | TAAR1 176/4885MEN1 3927/4885KMT2A 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.